Travere Therapeutics to Report First Quarter 2025 Financial Results
Travere Therapeutics (NASDAQ: TVTX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after U.S. financial markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The webcast and dial-in information can be accessed on the Investor page of Travere’s website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424213901/en/
Media:
888-969-7879
mediarelations@travere.com
Investors:
888-969-7879
IR@travere.com
Source: Travere Therapeutics, Inc.